International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature
Authors:
- Thomas GüntherTGThomas Günther
- Giovanni TulipanoGTGiovanni Tulipano
- Pascal DournaudPDPascal Dournaud
- Corinne BousquetCBCorinne Bousquet
- Zsolt CsabaZCZsolt Csaba
- Hans-Jürgen KreienkampHKHans-Jürgen Kreienkamp
- Amelie LuppALAmelie Lupp
- Márta KorbonitsMKMárta Korbonits
- Justo P. CastañoJusto P. Castaño
- Hans-Jürgen WesterHWHans-Jürgen Wester
- Michael CullerMCMichael Culler
- Shlomo MelmedSMShlomo Melmed
Top Cited Papers
Open Access
- 1 October 2018
- journal article
- review article
- Published by Elsevier in Pharmacological Reviews
- Vol. 70 (4) , 763-835
Abstract
Somatostatin, also known as somatotropin-release inhibitory factor, is a cyclopeptide that exerts potent inhibitory actions on hormone secretion and neuronal excitability. Its physiologic functions are mediated by five G protein-coupled receptors (GPCRs) called somatostatin receptor (SST)1-5. These five receptors share common structural features and signaling mechanisms but differ in their cellular and subcellular localization and mode of regulation. SST2 and SST5 receptors have evolved as primary targets for pharmacological treatment of pituitary adenomas and neuroendocrine tumors. In addition, SST2 is a prototypical GPCR for the development of peptide-based radiopharmaceuticals for diagnostic and therapeutic interventions. This review article summarizes findings published in the last 25 years on the physiology, pharmacology, and clinical applications related to SSTs. We also discuss potential future developments and propose a new nomenclature.Keywords
This publication has 769 references indexed in Scilit:
- Place of Preoperative Treatment of Acromegaly with Somatostatin Analog on Surgical Outcome: A Systematic Review and Meta-AnalysisPLOS ONE, 2013
- Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer: A Systematic Diagnostic AttemptClinical Genitourinary Cancer, 2012
- Somatostatin receptor subtype-4 agonist NNC 26–9100 decreases extracellular and intracellular Aβ1–42 trimersEuropean Journal of Pharmacology, 2012
- Phosphorylation of sst2 Receptors in Neuroendocrine Tumors after Octreotide Treatment of PatientsThe American Journal of Pathology, 2012
- Association between somatostatin receptor 5 gene polymorphisms and pancreatic cancer risk and survivalCancer, 2011
- The Conserved Bardet-Biedl Syndrome Proteins Assemble a Coat that Traffics Membrane Proteins to CiliaCell, 2010
- Pituitary somatostatin receptor signalingTrends in Endocrinology & Metabolism, 2010
- Design and in Vitro Characterization of Highly sst2-Selective Somatostatin Antagonists Suitable for RadiotargetingJournal of Medicinal Chemistry, 2008
- Somatostatin: An endogenous antiepilepticMolecular and Cellular Endocrinology, 2008
- Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumoursEuropean Journal of Nuclear Medicine and Molecular Imaging, 2008